Systematic Analysis of the Role of SLC52A2 in Multiple Human Cancers

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2022 Jan 7

PMID 34991609

Citations 8

Authors

Lilong Zhang

Man Li

Zhoujun Cui

Dongqi Chai

Yongjun Guan

Chen Chen

Weixing Wang

Affiliations

Soon will be listed here.

Abstract

Background: In humans, riboflavin must be obtained through intestinal absorption because it cannot be synthesized by the body. SLC52A2 encodes a membrane protein belonging to the riboflavin transporter protein family and is associated with a variety of diseases. Here, we systematically explore its relevance to multiple human tumors.

Methods: We analyzed the association of SLC52A2 with 33 tumors using publicly available databases such as TCGA and GEO. We verified the SLC52A2 expression in hepatocellular carcinoma, gastric cancer, colon cancer, and rectal cancer using immunohistochemistry.

Results: We report that SLC52A2 was highly expressed in almost all tumors, and the immunohistochemical results in the hepatocellular, gastric, colon, and rectal cancers were consistent with the above. SLC52A2 expression was linked to patient overall survival, disease-specific survival, progression-free interval, diagnosis, mutations, tumor mutational burden, microsatellite instability, common immune checkpoint genes, and immune cells infiltration. Enrichment analysis showed that SLC52A2 was mainly enriched in oocyte meiosis, eukaryotic ribosome biogenesis, and cell cycle. In hepatocellular carcinoma, the SLC52A2 expression is an independent prognostic factor. The SNHG3 and THUMPD3-AS1/hsa-miR-139-5p-SLC52A2 axis were identified as potential regulatory pathways in hepatocellular carcinoma.

Conclusion: In conclusion, we have systematically described for the first time that SLC52A2 is closely associated with a variety of tumors, especially hepatocellular carcinoma.

Citing Articles

Epigenetics Meets CAR-T-Cell Therapy to Fight Cancer.

Santourlidis S, Arauzo-Bravo M, Erichsen L, Bendhack M Cancers (Basel). 2024; 16(10).

PMID: 38792020 PMC: 11119853. DOI: 10.3390/cancers16101941.

The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma.

Wu Z, Zhang L, Li X, Liu L, Kuang T, Qiu Z Sci Rep. 2024; 14(1):10662.

PMID: 38724606 PMC: 11082141. DOI: 10.1038/s41598-024-60342-w.

Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights.

Zhang P, Pei S, Zhou G, Zhang M, Zhang L, Zhang Z J Cell Mol Med. 2024; 28(8):e18284.

PMID: 38597415 PMC: 11005461. DOI: 10.1111/jcmm.18284.

Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).

Ai L, Yi N, Qiu C, Huang W, Zhang K, Hou Q Int J Oncol. 2024; 64(5).

PMID: 38456493 PMC: 11000534. DOI: 10.3892/ijo.2024.5634.

Integration of genomics and transcriptomics highlights the crucial role of chromosome 5 open reading frame 34 in various human malignancies.

Li Y, Zhang Y, Sun D, Zhang X, Long S, Feng J Aging (Albany NY). 2023; 15(23):14384-14410.

PMID: 38078888 PMC: 10756085. DOI: 10.18632/aging.205310.

References

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Tutino V, Defrancesco M, Tolomeo M, De Nunzio V, Lorusso D, Paleni D . The Expression of Riboflavin Transporters in Human Colorectal Cancer. Anticancer Res. 2018; 38(5):2659-2667. DOI: 10.21873/anticanres.12508. View

Ruffell B, Coussens L . Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015; 27(4):462-72. PMC: 4400235. DOI: 10.1016/j.ccell.2015.02.015. View

Zhang C, Lv J, Gong L, Yu L, Chen X, Zhou H . Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health. 2016; 13(9). PMC: 5036725. DOI: 10.3390/ijerph13090892. View

Overman M, Lonardi S, Wong K, Lenz H, Gelsomino F, Aglietta M . Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018; 36(8):773-779. DOI: 10.1200/JCO.2017.76.9901. View

Zhang Y, Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. PMC: 7395159. DOI: 10.1038/s41423-020-0488-6. View

Eli M, Li D, Zhang W, Kong B, Du C, Wumar M . Decreased blood riboflavin levels are correlated with defective expression of RFT2 gene in gastric cancer. World J Gastroenterol. 2012; 18(24):3112-8. PMC: 3386325. DOI: 10.3748/wjg.v18.i24.3112. View

Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View

Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M . Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clin Cancer Res. 2015; 21(21):4960-9. DOI: 10.1158/1078-0432.CCR-14-3173. View

10.

Ito A, Kondo S, Tada K, Kitano S . Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int. 2015; 2015:605478. PMC: 4486755. DOI: 10.1155/2015/605478. View

11.

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2019; 51(2):411-412. DOI: 10.1016/j.immuni.2019.08.004. View

12.

Cheng L, Zhang Q, Yang S, Yang Y, Zhang W, Gao H . A 4-gene panel as a marker at chromosome 8q in Asian gastric cancer patients. Genomics. 2013; 102(4):323-30. DOI: 10.1016/j.ygeno.2013.05.004. View

13.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

14.

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

15.

Yonezawa A, Inui K . Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Mol Aspects Med. 2013; 34(2-3):693-701. DOI: 10.1016/j.mam.2012.07.014. View

16.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

17.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

18.

DeStefanis R, Kratz J, Emmerich P, Deming D . Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr Colorectal Cancer Rep. 2019; 15(2):61-69. PMC: 6528813. DOI: 10.1007/s11888-019-00430-6. View

19.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

20.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View